Overview

Pulmonary arterial hypertension (PAH) management increasingly relies on structured risk assessment to guide treatment decisions, yet many patients remain above low-risk status despite available therapies. Clinicians are often challenged with determining when risk assessment findings should prompt treatment modification, how to integrate hemodynamic and clinical data into decision-making, and how to balance disease control with treatment burden and patient preferences.

During this mini-module series, Dr. Vallerie McLauglin explores practical approaches to translating risk assessment into action. Through expert-led insights and real-world clinical cases, participants examine when to escalate therapy, when continued observation may be appropriate, and when treatment simplification or de-escalation may be considered in carefully selected patients. Particular emphasis is placed on shared decision-making, aligning treatment intensity with clinical need, and applying evidence-based strategies that support individualized care and improved outcomes for patients with PAH.